OPKO Health, Inc. (OPK) said Wednesday that it has signed a research and license agreement with a prominent Mexican professor of ophthalmology for a topically active formulation of the anti-VEGF antibody, ranibizumab, utilizing OPKO proprietary drug delivery technology.
The technology will initially target the development of the ranibizumab product to treat diabetic macular edema, or DME, but the delivery system will also be studied with other pharmaceutical products to treat DME and other eye diseases.
Dr. Frost, chairman and chief executive officer, of OPKO, said, "Presently, ranibizumab is only approved for delivery by intra-vitreal injection. We believe the development of a topical VEGF antibody formulation would result in substantial benefits to patients."
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.